Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor...

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR) mutations, specifically exon 19 deletions and L858R in exon 21, are common in non-small-cell lung cancer (NSCLC).
• While treatments for these common EGFR mutations are established, effective therapies for NSCLC patients with EGFR exon 20 insertion mutations are less defined.
• This study addresses the need for verified treatment strategies for advanced NSCLC patients harboring EGFR exon 20 insertions.

Purpose of the Study:

• To investigate the clinical response to various first-line treatments, including chemotherapy and tyrosine kinase inhibitors (TKIs), in advanced NSCLC patients with EGFR exon 20 insertion mutations.
• To evaluate the efficacy of different treatment regimens in this specific patient subgroup.
• To identify potential treatment benefits associated with specific chemotherapy agents or TKI responses.

Main Methods:

• A cohort of 3805 NSCLC patients was screened for EGFR mutations.
• EGFR exon 20 insertion mutations were identified in 84 patients (4.0% of those with EGFR mutations).
• The effectiveness of different first-line chemotherapy and TKI treatments was analyzed in patients with EGFR exon 20 insertions.

Main Results:

• Pemetrexed-containing chemotherapy regimens demonstrated significantly better progression-free survival (6.2 vs. 2.7 months) and overall survival (28.0 vs. 15.4 months) compared to non-pemetrexed regimens.
• Most patients with EGFR exon 20 insertions showed a poor response to tyrosine kinase inhibitors (TKIs).
• A specific mutation, Ala763_Tyr764insPheGlnGluAla (A763_Y764 insFQEA), was associated with a favorable response to TKIs.

Conclusions:

• EGFR exon 20 insertion mutations represent a significant subset of EGFR-mutated NSCLC.
• Treatment outcomes for advanced NSCLC with exon 20 insertions can vary based on the specific insertion type and the chosen first-line therapy.
• Pemetrexed-based chemotherapy shows promise, while TKI efficacy is limited, with exceptions for specific mutations.